Immune checkpoint inhibitors for cancer and venous thromboembolic events
Source: docwirenews, October 2021
BACKGROUND: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. There are limited data on the risk for developing venous thromboembolism (VTE) among patients on an ICI.
